Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
Abstract
Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
참고문헌 (25)
- Annual report of cancer statistics in Korea in 2015, "Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2017)
- Okamoto A, "Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary", Int J Gynecol Cancer, 24(9 Suppl 3), pp.S20~S25 (2014)
- Machida H, "Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015 : a JSGO-JSOG joint study", Gynecol Oncol, 153, pp.589~596 (2019)
- Gadducci A, "Novel insights on the malignant transformation of endometriosis into ovarian carcinoma", Gynecol Endocrinol, 30, pp.612~617 (2014)
- Hogen L, "Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?", Gynecol Oncol, 147, pp.54~60 (2017)
- Oseledchyk A, "Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era : a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013", Ann Oncol, 28, pp.2985~2993 (2017)
- Jones S, "Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma", Science, 330, pp.228~231 (2010)
- Wiegand KC, "ARID1A mutations in endometriosis-associated ovarian carcinomas", N Engl J Med, 363, pp.1532~1543 (2010)
- Ayhan A, "Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma", Int J Gynecol Cancer, 22, pp.1310~1315 (2012)
- Katagiri A, "Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma", Mod Pathol, 25, pp.282~288 (2012)
- Yamamoto S, "Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations", Mod Pathol, 25, pp.615~624 (2012)
- Anglesio MS, "Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010", Gynecol Oncol, 121, pp.407~415 (2011)
- Yamamoto A, "A higher prevalence of endometriosis among Asian women does not contribute to poorer IVF outcomes", J Assist Reprod Genet, 34, pp.765~774 (2017)
- 김세익, "Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012", Journal of Gynecologic Oncology, 27(1), pp.1~10 (2016), 대한부인종양학회
- 손주혁, "Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma", Obstetrics & Gynecology Science, 62(1), pp.27~34 (2019), 대한산부인과학회[DOI]
- Bai H, "Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma : experiences at three academic institutions", Gynecol Oncol, 143, pp.526~531 (2016)
- Kim HS, "Effect of endometriosis on the prognosis of ovarian clear cell carcinoma : a two-center cohort study and meta-analysis", Ann Surg Oncol, 22, pp.2738~2745 (2015)
- Orezzoli JP, "Prognostic implication of endometriosis in clear cell carcinoma of the ovary", Gynecol Oncol, 110, pp.336~344 (2008)
- Park JY, "Significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma", Int J Gynecol Cancer, 28, pp.11~18 (2018)
- Duska LR, "When 'never-events' occur despite adherence to clinical guidelines : the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes", Gynecol Oncol, 116, pp.374~377 (2010)
- Ye S, "Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma : a 12-year retrospective study", PLoS One, 10, pp.e0121818~ (2015)
- Oliver KE, "An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy : an NRG Oncology", Gynecologic Oncology Group experience, 2017, pp.147, 243~249
- Ledermann JA, "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi24~vi32 (2013)
- "Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2019)" (2019)[URL]
- Trimbos JB, "International Collaborative Ovarian Neoplasm trial 1and Adjuvant ChemoTherapy In Ovarian Neoplasm trial : two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma", J Natl Cancer Inst, 95, pp.105~112 (2003)